Plasma Derived Medicine Market Booming with Immunotherapy Advances and Expanding Rare Disease Applications, 2025-2032

The plasma derived medicine industry is witnessing substantial transformations driven by advancements in biotechnology and rising prevalence of immune disorders and chronic diseases worldwide. Increasing adoption across therapeutic areas spanning hematology, immunology, and infectious diseases is shaping robust growth trajectories for this sector. Global plasma derived medicine market is estimated to be valued at USD 19.87 Bn in 2025 and is expected to reach USD 32.77 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 7.4% from 2025 to 2032.

Get a Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/4929

➤Analyst Opinion

● A surge in global plasma collection capacity is a critical supply-side indicator influencing market growth. Recent expansions in plasma collection centers, particularly across the U.S. and Germany, contributed to a 12% rise in plasma volume in 2024 alone, underpinning increased availability of raw material essential for production.

● Demand-side dynamics illustrate broadening immunoglobulin applications, especially intravenous immunoglobulin (IVIG) therapy for autoimmune disorders. Between 2023 and 2025, IVIG consumption grew by approximately 9% annually, driven by rising treatment adoption for conditions such as chronic inflammatory demyelinating polyneuropathy (CIDP).

➤Market Taxonomy and Regional coverage of Report

● By Product Type: Immunoglobulins, Albumin, Coagulation Factors, Others
● By Application: Immunodeficiency Disorders, Hematology Diseases, Infectious Diseases, Others
● By End-User: Hospitals, Clinics, Research Laboratories, Others

Regional and Country Analysis:

● North America: U.S. and Canada
● Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
● Europe: Germany, U.K., Spain, France, Italy, Benelux, Denmark, Norway, Sweden, Russia, and Rest of Europe
● Asia Pacific: China, Taiwan, India, Japan, South Korea, Indonesia, Malaysia, Philippines, Singapore, Australia, and Rest of Asia Pacific
● Middle East & Africa: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates, Israel, South Africa, North Africa, Central Africa, and Rest of MEA

Buy the Complete Report with an Impressive Discount (Up to 25% Off) at: https://www.coherentmarketinsights.com/insight/buy-now/4929

➤Leading Companies of the Market

● CSL Limited
● Grifols S.A.
● Takeda Pharmaceutical Company Limited
● Octapharma AG
● Kedrion S.p.A
● Octapharma Plasma Inc.
● Bio Products Laboratory
● LFB Group
● Biotest AG
● BPL Plasma Inc.
● Sanquin Blood Supply Foundation
● BioLife Plasma Services
● Canadian Blood Services
● HemaCare Corporation
● Haema AG
● GC Pharma
● China Biologic Products Holdings, Inc.
● Shanghai RAAS Blood Products Co., Ltd.
● Suzhou Medical Systems Biotechnology Co., Ltd.

Several market players have recently intensified investments in capacity expansions and strategic acquisitions to strengthen their regional footprint. For example, CSL Limited's acquisition of local plasma centers in 2024 resulted in a 15% incremental market share in North America. Takeda's collaboration with specialized biotechnological firms accelerated development in novel coagulation factor therapies, boosting product portfolio diversity and driving higher revenue growth in Asia Pacific.

➤Key Growth Drivers Fuelling Market Expansion

The rising incidence of immune and hematological disorders globally contributes significantly to market revenue growth. The World Health Organization recently reported a 7% year-over-year increase in immune-mediated diseases, expanding demand for plasma derived therapies. Technological advancements in plasma fractionation and purification techniques have enhanced product yield and safety profiles, directly impacting market size by improving therapeutic efficacy. Expanding plasma collection infrastructure, particularly across emerging economies such as India and Brazil, facilitates wider market access, accounting for enhanced regional business growth and industry share. Additionally, healthcare policy reforms endorsing the use of plasma derived medicines within national immunization and treatment protocols act as pivotal market drivers, encouraging increased adoption and investment.

➤Key Reasons for Buying the Plasma Derived Medicine Report

✦ Comprehensive analysis of the changing competitive landscape
✦ Assists in decision-making processes for the businesses along with detailed strategic planning methodologies
✦ The report offers forecast data and an assessment of the plasma derived medicine market
✦ Helps in understanding the key product segments and their estimated growth rate
✦ In-depth analysis of market drivers, restraints, trends, and opportunities
✦ Comprehensive regional analysis of the plasma derived medicine market
✦ Extensive profiling of the key stakeholders of the business sphere
✦ Detailed analysis of the factors influencing the growth of the plasma derived medicine market

Buy the Complete Report with an Impressive Discount (Up to 25% Off) at: https://www.coherentmarketinsights.com/insight/buy-now/4929

➤ Emerging Trends and Market Shift

The plasma derived medicine market is progressively shifting toward personalized therapeutics, including tailored immunoglobulin dosing regimens based on patient genomics. In 2024, nearly 20% of plasma derived medicine product launches incorporated precision medicine attributes, reflecting this trend. Moreover, integration of digital health solutions for plasma donor management and traceability is gaining momentum, enhancing supply chain transparency. Another significant trend is the growing emphasis on recombinant substitutes, aiming to supplement plasma-derived proteins and mitigate supply risks. For example, global utilization of recombinant coagulation factors increased by 11% in 2025 compared to the previous year, positioning them as emerging competitors within the broader market scope.

➤High-Impact Market Opportunities by Segment and Region

Within the immunoglobulins segment, opportunities lie in expanding therapeutic indications for neurological conditions such as multiple sclerosis, where demand is projected to increase by 13% annually through 2030. The albumin segment offers growth potential driven by rising surgical procedures and critical care needs in aging populations, especially in developed countries. In the infectious diseases application segment, the growing prevalence of emerging viral infections like COVID-19 and hepatitis is stimulating the demand for passive immunization products. Regionally, Asia Pacific stands out as a high-impact market opportunity with ongoing plasma center establishments and favorable regulatory reforms, projected to witness a CAGR exceeding 10% through 2032, reflecting accelerated plasma derived medicine market growth.

❓ Frequently Asked Questions

1. Who are the dominant players in the Plasma Derived Medicine market?
Dominant market companies include CSL Limited, Grifols S.A., Takeda Pharmaceutical Company Limited, and Octapharma AG, each commanding significant market share through strategic expansion, product innovation, and global plasma collection networks.

2. What will be the size of the Plasma Derived Medicine market in the coming years?
The market size is expected to grow from USD 34.2 billion in 2025 to USD 58.7 billion by 2032, reflecting a CAGR of 8.1%, driven by increasing disease prevalence and expanded therapeutic applications.

3. Which end users industry has the largest growth opportunity?
Hospitals remain the largest end-user segment, fueled by rising demand for plasma derived therapeutics for immune deficiencies, hematological and infectious diseases in inpatient and outpatient settings.

4. How will market development trends evolve over the next five years?
Trends indicate increased adoption of personalized medicine, digital donor management, recombinant protein alternatives, and enhanced plasma collection infrastructure, reshaping market dynamics and business growth trajectories.

5. What is the nature of the competitive landscape and challenges in the Plasma Derived Medicine market?
The competitive landscape is defined by consolidation efforts, technological breakthroughs, and regional expansion. Key challenges include plasma supply constraints, regulatory complexities, and market pricing pressures.

📞 Contact Us:
Mr. Shah
Coherent Market Insights Pvt. Ltd,
U.S.: + 12524771362
U.K.: +442039578553
AUS: +61-2-4786-0457
INDIA: +91-848-285-0837

About CMI:

Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

This release was published on openPR.